At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
AGN-229666 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AGN-229666 for the Treatment of Allergic Conjunctivitis
In Brief
A Phase 2 clinical trial evaluating AGN-229666 and vehicle of AGN-229666 for Allergic Conjunctivitis. Completed, enrolled 90 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedDec 2012
Primary CompletionJan 2013
Study CompletionFeb 2013
TodayJul 2026
First PostedDec 21, 2012
Enrollment StartOct 1, 2012
Primary CompletionJan 1, 2013
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.5 years ago
Interventions
AGN-229666drug
One drop of AGN-229666 into each eye on Day 1 and Day 15.
vehicle of AGN-229666other
One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.